Pitt Study Reframes Understanding of Graft-Versus-Host Disease (upmc.com)
Published in Immunity, the study showed in a mouse model that GVHD, which often affects the skin, gut and liver, is maintained by donor T cells that seed those tissues soon after transplant and not by the continual recruitment of T cells from the blood as previously thought. Warren Shlomchik, MD, director of the Hematopoietic Stem Cell Transplant and Cell Therapy program at UPMC Hillman Cancer Center, was the study’s co-senior author.
New Analysis Sheds Light on Link Between Ovulation and Ovarian Cancer - UPMC & Pitt Health Sciences News Blog
Senior author Dr. Francesmary Modugno, professor of obstetrics, gynecology and reproductive sciences at Magee-Womens Research Institute and UPMC Hillman Cancer Center, led an international team of researchers for this study.
University of Pittsburgh Receives $11M NIH SPORE Award | UPMC Physician Resources
The University of Pittsburgh was awarded a five-year, $11.2 million grant from the National Institutes of Health (NIH) to support a Head and Neck Cancer Specialized Program of Research Excellence (SPORE) in 2022. The award will be led by Robert L. Ferris, MD, PhD, Director of UPMC Hillman Cancer Center, and Heath Skinner, MD, PhD, Chair and Associate Professor, Department of Radiation Oncology.
UPMC/Pitt Breast Cancer Scientists Receive Funding for Research | UPMC Physician Resources
Steffi Oesterreich, PhD, and Adrian V. Lee, PhD, breast cancer researchers at UPMC Hillman Cancer Center and Magee-Womens Research Institute, along with Wendie Berg, MD, PhD, professor of radiology at UPMC Magee-Womens Hospital, and all from the University of Pittsburgh School of Medicine, are among the nation’s leading breast cancer scientists to receive funding from the Breast Cancer Research Foundation (BCRF). Also receiving funding is Norman Wolmark, MD, FACS, chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP), director of the National Cancer Institute Cooperative Group Clinical Trials at UPMC Hillman and professor of surgery at Pitt.
Advancing the Field of CAR-T Cells | UPMC Hillman Cancer Center
Researchers at the UPMC Hillman Cancer Center Tumor Microenvironment Center developed a new model that can be used by immunologists to further the understanding of CAR-T cell biology and identified a new possible human CAR-T cell target.
Chemotherapy-Resistant Ovarian Cancer Cells Protect Their Neighbors - UPMC & Pitt Health Sciences News Blog
Published in Clinical Cancer Research, the study investigated chemotherapy-resistant cancer cells called quiescent cells.
Important Cancer Screenings Still on the Decline - UPMC & Pitt Health Sciences News Blog
A study from the American Cancer Society, published in the Journal of Clinical Oncology indicates that cancer screenings remain below pre-pandemic levels for the second consecutive year. Dr. Robert Ferris, director of UPMC Hillman Cancer Center, discusses the importance of early screening.
Disparities in Women's Cancer Care | UPMC Hillman Cancer Center
Alexander B. Olawaiye, MD, professor of gynecologic oncology at UPMC Magee-Womens Hospital and member of the cancer therapeutics program at UPMC Hillman Cancer Center, focuses much of his work on how these disparities affect cancer care and cancer research specifically in women’s cancers.
Study of Immune ‘Neighborhoods’ Highlights Macrophages as Key Players in Invasive Breast Cancers - UPMC & Pitt Health Sciences News Blog
Dr. Dario Vignali, distinguished professor and interim chair of the Pitt School of Medicine Department of Immunology and associate director for scientific strategy and co-leader of the Cancer Immunology & Immunotherapy Program at UPMC Hillman Cancer Center, was co-senior author.
Customizing T Cell-Based Immunotherapies in a ‘SNAP’ | UPMC Physician Resources
University of Pittsburgh researchers have developed a universal receptor system that allows T cells to recognize any cell surface target, enabling highly customizable CAR T cell and other immunotherapies for treating cancer and other diseases. The senior author of the study was Jason Lohmueller, PhD, assistant professor of surgery and immunology in the division of surgical oncology and investigator at UPMC Hillman Cancer Center.
Study Shows Diet and Probiotics Boost Melanoma Immunotherapy Response (upmc.com)
In mice with melanoma, probiotic bacteria travel from the gut and establish in tumors, where they directly stimulate immune cells to make cancer immunotherapy more effective, according to a new study led by University of Pittsburgh researchers.
Dr. Wei Du publishes new findings on the role of AREG in compromising hematopoietic stem cell maintenance during DNA damage in “Blood” | Department of Medicine (pitt.edu)
Dr. Wei Du and her team published: “LepR+ niche cell-derived AREG compromises hematopoietic stem cell maintenance under conditions of DNA repair deficiency and aging”, published recently in the journal Blood.
Dr. Samit Ghosh awarded new NIH-NIDDK R01 for his work on chronic kidney disease associated with sickle cell disorders | Department of Medicine (pitt.edu)
Dr. Samit Ghosh has received a new R01 from NIDDK titled “Renal endothelium and the development of chronic kidney disease in sickle cell disorders”. With this funding Dr. Ghosh will study Progressive chronic kidney disease (CKD) associated with intravascular hemolysis in sickle cell disease (SCD).
Cancer-Infecting Virus ‘Warms Up’ Cold Tumors and Improves Immunotherapy - UPMC & Pitt Health Sciences News Blog
Dr. Greg Delgoffe, associate professor of immunology at Pitt’s School of Medicine and director of the Tumor Microenvironment Center at UPMC Hillman Cancer Center was senior author of the study.
Enhancing Antitumor Immunity Targeting Regulatory T Cells | UPMC Physician Resources
Published in Science Immunology, researchers led by Dario Vignali, PhD, distinguished professor and chair of the Department of Immunology and member of UPMC Hillman Cancer Center, identified a genetic mechanism to enhance an immune system’s antitumor activity.
Expert Opinions on Breast Cancer Research Innovations | UPMC Physician Resources
UPMC Hillman’s Dr. Zervantonakis, Dr. Lee, and Dr. Oesterreich discuss the impact of breast cancer research.
Cancer Drug That Targets Two Immune-Evading Tumor Tactics Performs Well in Early Clinical Trial - UPMC & Pitt Health Sciences News Blog
Dr. Jason Luke, director of the Immunotherapy and Drug Development Center at UPMC Hillman and associate professor of hematology and oncology at the University of Pittsburgh School of Medicine, was lead author of the study.
Immunotherapy Drug is Well Tolerated in Lung Cancer Patients with Limited Physical Function, Study Suggests - UPMC & Pitt Health Sciences News Blog
Dr. Liza Villaruz, associate professor of medicine at the University of Pittsburgh and co-leader of the Immunotherapy and Drug Development Center at UPMC Hillman, was senior author of the study.
UPMC Presbyterian Shadyside Nationally Ranked for Excellence in Oncology
